Skip to main content

Pegaptanib ophthalmic Pregnancy and Breastfeeding Warnings

Pegaptanib ophthalmic is also known as: Macugen

Pegaptanib ophthalmic Pregnancy Warnings

Use during pregnancy only if clearly needed.

US FDA pregnancy category: B

Comments: This drug crosses the placenta in animals.

Animal studies did not reveal evidence of teratogenicity, fetal mortality, or maternal toxicity at IV doses of up to 40 mg/kg/day (about 7000 times the recommended human dose). No information is available to evaluate the drug effect on mating or fertility. There are no controlled data in human pregnancy.

US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

See references

Pegaptanib ophthalmic Breastfeeding Warnings

Use with caution during breastfeeding.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Macugen (pegaptanib ophthalmic)." OSI Pharmaceuticals Inc (2004):

References for breastfeeding information

  1. "Product Information. Macugen (pegaptanib ophthalmic)." OSI Pharmaceuticals Inc (2004):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.